On Friday, Cassava Sciences Inc (SAVA) stock saw a decline, ending the day at $28.49 which represents a decrease of $-3.38 or -10.61% from the prior close of $31.87. The stock opened at $28.08 and ...

Casava stock falls as the company agrees to pay a cumulative fine exceeding $40 million to settle misleading claims charges ...

The Securities & Exchange Commission (SEC) has accused Cassava's founder and former chief executive Remi Barbier and former ...

Local markets are up this morning, with the benchmark moving through a new record high as Energy and Materials stocks drove ...

ASX could hit record high despite mixed bag on Wall Street. US stocks expected to outperform bonds as Fed cuts rates.

Before market open, Cassava announced that it has reached agreement with the U.S. Securities and Exchange Commission (SEC) to ...

Biopharmaceutical company Cassava Sciences, along with founder Remi Barbier and former Senior Vice President of Neuroscience Lindsay Burns, PhD, will pay more than $40 million to settle allegations ...

Neuroscience-focused biopharmaceutical company Cassava Sciences Inc. and two former executives have agreed to pay over $40 ...

A former Alzheimer's researcher manipulated the results of a Cassava Sciences drug, with the pharmaceutical company and its ...

Despite the settlement, the Securities and Exchange Commission on Thursday sued Cassava Sciences in the Western District Court of Texas, claiming that the company misled investors regarding the Phase ...

Key Takeaways Cassava Sciences and two former executives agreed to pay more than $40 million in a settlement with the SEC.The ...

What comes next for Pfizer's Oxbryta sickle cell drug —Cassava Sciences' SEC charges —Bristol's new schizophrenia treatment ...